← Leaderboards
Eileen Shiuan
Vanderbilt University
$114,704
Attributed
$114,704
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $45K · FY2017–20$50K$37.5K$25K$12.5K$0
'17
'18
'19
'20
Funding mix
By agency
NIH$114,704 · 1
By mechanism
F30$114,704 · 1
Top collaborators
No co-investigators on record.
Most similar at Vanderbilt University
Same institution · by research overlap
- Dana M Brantley-Sieders$4,304,141
- Pierre P Massion$18,568,000
- Ann Richmond$15,857,391
- Jennifer A Pietenpol$43,416,854
- Jordan D Berlin$14,361,518
Others in their field
Other Emerging Leaders on “Complex”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$58,784,651
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$41,535,815
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
ComplexCytokineAffectCoculture TechniquesAlternative TreatmentCrispr/Cas TechnologyApoptosisBaseBone Marrow TransplantationActionable MutationCancer CellCancer Cell LineCancer EtiologyCancer ImmunotherapyCancer ModelCancer PatientCell KillingCellsCell Surface ProteinsCell TypeCessation Of LifeChemotherapy-Oncologic ProcedureClinicDrug Resistance
Grant awards (4)
Investigating the role of EphA2 receptor tyrosine kinase in anti-tumor immunity mediated through programmed cell death ligand 2 (PD-L2) in non-small cell lung cancer (NSCLC)$11,778
F30 · FY2020 · CA · contact PI
Investigating the role of EphA2 receptor tyrosine kinase in anti-tumor immunity mediated through programmed cell death ligand 2 (PD-L2) in non-small cell lung cancer (NSCLC)$45,016
F30 · FY2019 · CA · contact PI
Investigating the role of EphA2 receptor tyrosine kinase in anti-tumor immunity mediated through programmed cell death ligand 2 (PD-L2) in non-small cell lung cancer (NSCLC)$29,198
F30 · FY2018 · CA · contact PI
Investigating the role of EphA2 receptor tyrosine kinase in anti-tumor immunity mediated through programmed cell death ligand 2 (PD-L2) in non-small cell lung cancer (NSCLC)$28,712
F30 · FY2017 · CA · contact PI